SCPHARMACEUTICALS INC. Operating Costs and Expenses
SCPHARMACEUTICALS INC. reported Operating Costs and Expenses of $30.34 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingCostsAndExpenses · last filed 2025-08-07
- SCPHARMACEUTICALS INC. operating costs and expenses for the quarter ending 2025-06-30 was $30.34M, a 34.91% increase year-over-year.
- SCPHARMACEUTICALS INC. operating costs and expenses for the quarter ending 2025-03-31 was $29.51M, a 34.39% increase year-over-year.
- SCPHARMACEUTICALS INC. operating costs and expenses for the quarter ending 2024-12-31 was $28.49M, a 33.44% increase year-over-year.
- SCPHARMACEUTICALS INC. operating costs and expenses for the quarter ending 2024-09-30 was $28.17M, a 51.18% increase year-over-year.
- SCPHARMACEUTICALS INC. operating costs and expenses for fiscal 2024 was $101.11M, a 46.56% increase from fiscal 2023.
- SCPHARMACEUTICALS INC. operating costs and expenses for fiscal 2023 was $68.99M, a 90.80% increase from fiscal 2022.
- SCPHARMACEUTICALS INC. operating costs and expenses for fiscal 2022 was $36.16M.
| Period end | Operating Costs and Expenses 3 month | Operating Costs and Expenses 6 month | Operating Costs and Expenses 9 month | Operating Costs and Expenses 12 month |
|---|---|---|---|---|
| 2025-06-30 | $30.34M 10-Q · filed 2025-08-07 | $59.84M 10-Q · filed 2025-08-07 | $88.34M derived: sum of 3 quarters · filed 2025-08-07 | $116.51M derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | $29.51M 10-Q · filed 2025-05-14 | $58.00M derived: sum of 2 quarters · filed 2025-05-14 | $86.17M derived: sum of 3 quarters · filed 2025-05-14 | $108.66M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-12-31 | $28.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $56.66M derived: sum of 2 quarters · filed 2025-03-19 | $79.15M derived: sum of 3 quarters · filed 2025-08-07 | $101.11M 10-K · filed 2025-03-19 |
| 2024-09-30 | $28.17M 10-Q · filed 2024-11-13 | $50.66M derived: sum of 2 quarters · filed 2025-08-07 | $72.61M 10-Q · filed 2024-11-13 | $93.97M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-06-30 | $22.48M 10-Q · filed 2025-08-07 | $44.44M 10-Q · filed 2025-08-07 | $65.80M derived: sum of 3 quarters · filed 2025-08-07 | $84.43M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $21.96M 10-Q · filed 2025-05-14 | $43.31M derived: sum of 2 quarters · filed 2025-05-14 | $61.95M derived: sum of 3 quarters · filed 2025-05-14 | $77.33M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $21.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $39.99M derived: sum of 2 quarters · filed 2025-03-19 | $55.37M derived: sum of 3 quarters · filed 2025-03-19 | $68.99M 10-K · filed 2025-03-19 |
| 2023-09-30 | $18.64M 10-Q · filed 2024-11-13 | $34.02M derived: sum of 2 quarters · filed 2024-11-13 | $47.64M 10-Q · filed 2024-11-13 | $57.14M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $15.38M 10-Q · filed 2024-08-14 | $29.00M 10-Q · filed 2024-08-14 | $38.50M derived: sum of 3 quarters · filed 2024-08-14 | $48.50M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $13.62M 10-Q · filed 2024-05-14 | $23.12M derived: sum of 2 quarters · filed 2024-05-14 | $33.11M derived: sum of 3 quarters · filed 2024-05-14 | $42.53M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $9.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $19.50M derived: sum of 2 quarters · filed 2024-03-13 | $28.92M derived: sum of 3 quarters · filed 2024-03-13 | $36.16M 10-K · filed 2024-03-13 |
| 2022-09-30 | $9.99M 10-Q · filed 2023-11-08 | $19.42M derived: sum of 2 quarters · filed 2023-11-08 | $26.66M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $9.42M 10-Q · filed 2023-08-10 | $16.66M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $7.24M 10-Q · filed 2023-05-10 |